-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
HFpEF affects more than 3 million Americans, and as society ages, the prevalence rate is increasing.
despite decades of research, it is difficult to develop treatments because of the heterogeneous nature of pathophysiology and the different effects of patient symptoms.
HFpEF can alter the structure of the heart, which occurs when the heart's muscle tissue thickens and hardens so that it cannot expand to fill up with enough blood to meet the body's needs.
HFpEF was associated with high rates of relapse to heart failure, emergency visits and emergency doctor appointments.
hospitalization was associated with a long-term prognosis deterioration, with about a quarter of patients admitted again for heart failure within a year of discharge.
Entresto has been approved in 115 countries around the world to treat reduced blood score heart failure (HFrEF).
in China, where it was approved for listing in 2017.
Entresto is a combination of the brain morphine enzyme inhibitor shakubaquo and the angiotensin-stressor antagonist python, which work better together.
the other hand, through shakubaquo to enhance the beneficial role of nitrate peptide system, play a role in the diuretic, diastolic blood vessels and protect the heart and so on.
the other hand, the role of renin-angiotensin-aldosterone (RAAS) is inhibited through salatin, which acts as a trachea, improves sodium retention and reduces heart load. the
Committee's positive decision was based on an analysis of comprehensive data on Theresto efficacy and safety, including paramount-HF and Phase 2 clinical trial PARAMOUNT data in phase 3 clinical trials conducted in HFpEF patients, and Phase 3 clinical trial data in HFrEF patients.
PARAGON-HF data show that Entersto has good safety characteristics in HFpEF patients, consistent with a large number of clinical and post-market experiences in HFrEF patients, and demonstrates Entersto's clinical benefits in HFpEF patients.
resources: novartis announces positive FDA Advisory Committee recommendation for use of entresto® to treat patients with HFpEF. Retrieved December 16, 2020, from。